Navigation Links
Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results
Date:3/11/2008

continues to pursue

development of SNS-595 in acute myeloid leukemia (AML). A Phase 1b

clinical trial of SNS-595 in combination with cytarabine in relapsed

or refractory AML patients is in progress. Sunesis plans to begin

enrollment in a Phase 2 clinical trial of SNS-595 on a weekly dose

schedule in previously untreated elderly AML patients in the first

half of 2008. Sunesis expects to report data later this year for

both AML clinical trials.

-- Results from a non-clinical study of SNS-032, a potent and selective

inhibitor of cyclin-dependent kinases (CDKs) 2, 7 and 9, were presented

at ASH. These data demonstrated that SNS-032 induces apoptosis in

chronic lymphocytic leukemia (CLL) cells. Furthermore, SNS-032's in

vitro activity compared favorably with flavopiridol in CLL cells

obtained from patients. SNS-032 currently is in a Phase 1 clinical

trial of patients with relapsed or refractory CLL or multiple myeloma.

To date, the drug has been well tolerated in this trial, and dose

escalation in both indications is expected to be completed this year.

-- Sunesis is continuing enrollment in its Phase 1 dose-escalating trial

of SNS-314, a potent and selective inhibitor of Aurora kinases A, B and

C, in advanced solid tumors. To date, SNS-314 has been well tolerated

and no dose-limiting toxicities have been observed. The company

expects to identify a maximum-tolerated dose in this Phase 1 clinical

trial this year.

-- In December, Sunesis and the Multiple Myeloma Research Consortium

(MMRC) announced a collaboration to evaluate the preclinical activity

of SNS-032 in multiple myeloma-relevant models and in primary disease

tissue, extending non-clinical studies performed by Sunesis.

-- In February 2008, Sunesis received
'/>"/>

SOURCE Sunesis Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Sunesis Pharmaceuticals to Present Interim Phase 2 Data for SNS-595 at the 39th Annual Meeting on Womens Cancer
2. Sunesis Pharmaceuticals Announces Milestone Payment from Inflammation Collaboration
3. Sunesis Pharmaceuticals Appoints Lesley A. Stolz, Ph.D., Vice President, Corporate and Business Development
4. Sunesis Pharmaceuticals to Report Third Quarter 2007 Financial Results
5. Sunesis Pharmaceuticals to Present Data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
6. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
7. Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008
8. Alseres Pharmaceuticals Presents Inosine and Dopamine Transporter (DAT) Blocker Preclinical Data at the American Society for Experimental NeuroTherapeutics (ASENT) Conference
9. Keryx Biopharmaceuticals Announces that SUN-MICRO Phase 3 Clinical Trial Fails to Meet Primary Efficacy Endpoint
10. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2007 Financial Results and Clinical Program Overview on March 12, 2008
11. Jazz Pharmaceuticals, Inc. Announces Webcast of March 13 Investor Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/27/2014)... MILAN , October 27, 2014 ... the right to produce, exhibit and sell its ... sought to impeach their patent.      ... After four years of fighting, the definitive judgement ... designs and produces innovative and accessible hi-tech prostheses ...
(Date:10/27/2014)... 2014 Called the NOAH Protocol, ... several types of pediatric brain cancer. The implications ... over 30 years of research and development. Amber ... that one mom's determination can make a difference. ... trick-or-treating, and it’s only fitting that we’ve received ...
(Date:10/26/2014)... 26, 2014 The report "Data ... Network Security Equipment, WAN Optimization Appliances]: Global Advancements, ... the data center networking market into various segments ... The report also identifies the factors driving this ... it along with the future roadmaps. , Browse ...
(Date:10/25/2014)... According to new market research ... Types (Colocation, Enterprise, Telecom), by Design Types (Electrical, ... 2, Tier 3, Tier 4) - Global Forecast ... the Data Center Construction Market into various segments ... This research report also identifies the factors driving ...
Breaking Biology Technology:Italian Lower Limb Prosthesis Company Wins Lawsuit Against German Giant Ottobock 2FDA Approves Breakthrough in Pediatric Brain Cancer - First in 30 Years 2FDA Approves Breakthrough in Pediatric Brain Cancer - First in 30 Years 3Data Center Networking Market by Ethernet Switches, SAN & Routers Worth $21.85 Billion by 2018 - New Report by MarketsandMarkets 2Data Center Networking Market by Ethernet Switches, SAN & Routers Worth $21.85 Billion by 2018 - New Report by MarketsandMarkets 3Data Center Networking Market by Ethernet Switches, SAN & Routers Worth $21.85 Billion by 2018 - New Report by MarketsandMarkets 4Data Center Construction Market Worth $22.73 Billion by 2019 - New Report by MarketsandMarkets 2Data Center Construction Market Worth $22.73 Billion by 2019 - New Report by MarketsandMarkets 3Data Center Construction Market Worth $22.73 Billion by 2019 - New Report by MarketsandMarkets 4
... Calif., July 26, 2011 Synterra Energy, Inc. ... and assets for waste biomass conversion from Pacific ... Lion Bio-Energy (Toledo, Ohio).  With the merger, Synterra ... bio-refineries for the economic production of renewable fuels, ...
... 26, 2011   At the ... Center for Devices and Radiologic Health of the United States ... Thursday July 21 in Gaithersburg, Maryland to review the results ... charge of the panel was to review the clinical data ...
... Neogen Corporation (NASDAQ: NEOG ) announced today that ... 31, increased 30% from the previous year to $22,839,000. Net ... compared to the prior year,s $0.76 per share. ... up from $140,509,000 in the company,s previous fiscal year. Both ...
Cached Biology Technology:Synterra Energy Merges Key Technologies to Commercialize Next Generation Integrated Bio-refinery 2FDA Advisory Panel Unanimously Recommends Approval of EXCOR(R) Pediatric Ventricular Assist Device for Use in the United States 2FDA Advisory Panel Unanimously Recommends Approval of EXCOR(R) Pediatric Ventricular Assist Device for Use in the United States 3FDA Advisory Panel Unanimously Recommends Approval of EXCOR(R) Pediatric Ventricular Assist Device for Use in the United States 4Neogen Reports 30% Increase in Net Income 2Neogen Reports 30% Increase in Net Income 3Neogen Reports 30% Increase in Net Income 4Neogen Reports 30% Increase in Net Income 5
(Date:10/29/2014)... decompose, their types and numbers of bugs and ... mean the difference between a closed case and ... using a more than $866,000 U.S. Department of ... these changing populations. The microbial communities may provide ... gender, race, socioeconomic relations and more, said Eric ...
(Date:10/29/2014)... research potential of the Barcode of Life Data ... Biodiversity Data Journal (BDJ) used ... imported these into a human-readable text developed in manuscript ... were used to study the species distributions of ten ... , BOLD is originally designed to support the generation ...
(Date:10/29/2014)... Ghrelin is a hormone released by the stomach and ... viewed as a psychoactive substance that primarily affects brain ... , This knowledge, combined with findings from animal ... the potential to stimulate alcohol craving. , Dr. Lorenzo ... found that, as they had anticipated, alcohol craving was ...
Breaking Biology News(10 mins):MSU partners with Detroit to investigate death scenes 2Go straight and publish: From Barcode of Life Data Systems to scholarly publishing systems 2Ghrelin stimulates an appetite for drinking alcohol 2
... CA) Researchers at the Burnham Institute for Medical Research ... intestinal protein leakage in mice, allowing the team to ... in an in vivo setting. Protein-losing enteropathy (PLE) encompasses ... into the digestive tract. One type of PLE ...
... the Hinode mission have shed new light on the Sun,s ... disrupt power grids, satellites and communications on Earth. The ... journal Science. , Data from Hinode, a Japanese (JAXA) mission ... role in driving the solar wind into space. The solar ...
... new and compelling argument for reducing fish harvests the ... short-term pain of lower catches for the long-term gain of ... ground-breaking study on fisheries over-exploitation. They say their findings, ... a key cause of over-fishing industry opposition to lower ...
Cached Biology News:Safe and effective therapy discovered for patients with protein-losing enteropathy 2Hinode: new insights on the origin of solar wind 2Economists: Reduce fish catch now for bigger net profits later 2Economists: Reduce fish catch now for bigger net profits later 3
... DNase is a preparation of deoxyribonuclease ... DNA to produce 3-hydroxyl oligonucleotides. This ... applications where maintaining the integrity of ... qualified for use with the Core ...
... Type Liquid. In 100 mM KCl, ... EDTA, 20% glycerol, pH 7.9. AVOID FREEZE/THAW CYCLES. ... monomeric protein of 765 amino acids encoded by ... both positive and negative supercoiled DNAs without the ...
Request Info...
... III digests duplex DNA in a 3'-> ... or nick, producing stretches of single-stranded DNA. ... Exonuclease III proceeds at a uniform rate ... rate of exonucleolytic excision of deoxyribonucleotides by ...
Biology Products: